<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Efficacy, safety and tolerability of <z:chebi fb="9" ids="46887">acetyl</z:chebi>-L-<z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> (ALC) were studied during the double-blind placebo-controlled 12-week trial in patients with mild (initial) <z:hpo ids='HP_0000726'>dementia</z:hpo> caused by the <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VD) </plain></SENT>
<SENT sid="1" pm="."><plain>ALC was administered in doses from 2250 to 3000 mg per day </plain></SENT>
<SENT sid="2" pm="."><plain>Patient's state was assessed with some scales (MMSE, CGI etc) and a battery of neuropsychological tests </plain></SENT>
<SENT sid="3" pm="."><plain>The treatment effect of ALC was 2,8 times higher than in placebo-treated patients </plain></SENT>
<SENT sid="4" pm="."><plain>The clinical improvement by CGI scores was significantly better in AD patients compared to VD and did not depend on the severity of baseline <z:e sem="disease" ids="C0679466" disease_type="Mental or Behavioral Dysfunction" abbrv="">cognitive deficit</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The drug was well-tolerated </plain></SENT>
<SENT sid="6" pm="."><plain>Carnicetine can be recommended in the abovementioned doses for treatment of early stages of AD and VD </plain></SENT>
</text></document>